ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex
ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex
Invitrogen™

ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex

ヒト免疫腫瘍チェックポイント14-Plex ProcartaPlex1パネルは、研究者がLuminex xMAPテクノロジーを使用して、1つのウェルで14個のタンパク質ターゲットを分析することで、がん研究を可能にします。このパネルを使用すると、T細胞の調整において重要な役割を果たす可溶型のタンパク質を同時に検出でき、T細胞の枯渇または刺激につながるため、抗腫瘍免疫応答が修正されます詳細を見る
製品番号(カタログ番号)数量
EPX14A-15803-90196テスト
製品番号(カタログ番号) EPX14A-15803-901
価格(JPY)
546,700
Each
お問い合わせください ›
数量:
96テスト

ヒト免疫腫瘍チェックポイント14-Plex ProcartaPlex1パネルは、研究者がLuminex xMAPテクノロジーを使用して、1つのウェルで14個のタンパク質ターゲットを分析することで、がん研究を可能にします。このパネルを使用すると、T細胞の調整において重要な役割を果たす可溶型のタンパク質を同時に検出でき、T細胞の枯渇または刺激につながるため、抗腫瘍免疫応答が修正されます。これらの可溶性バイオマーカーの分析は、経路の生物学上の光を放出するのに役立ちます。このパネルは、同じ研究領域で23の追加タンパク質ターゲットを提供する免疫腫瘍チェックポイント14-Plex ProcartaPlexパネル2(カタログ番号EPX140-15815-901)および免疫腫瘍チェックポイント9-Plex ProcartaPlexパネル3(カタログ番号EPX090-15820-901)を補完するものです。

ProcartaPlex事前設定済みパネルは、検体の組み合わせ性、干渉、交差反応性について広範にテストされており、最高レベルの検証と精度を提供します。すべての ProcartaPlex パネルには、アッセイの実行に必要な試薬が付属しています。

ターゲットリスト[ビーズ領域]:
免疫刺激:CD27 [27]、CD28 [15]、CD137(4-1BB)[26]、GITR [57]、HVEM [36]
免疫抑制:BTLA[52]、CD80 [61]、CD152(CTLA4)[33]、IDO [46]、LAG-3 [47]、PD-1 [65]、PD-L1 [66]、PD-L2 [67]、TIM-3 [14]

Luminexプラットフォーム用ProcartaPlexアッセイについて
ProcartaPlexイムノアッセイは、サンドイッチELISAの原則に基づいており、1つのタンパク質の複数のエピトープに結合した2つの特異的抗体を使用して、すべてのタンパク質ターゲットを同時に定量化します。ProcartaPlex マルチプレックスアッセイは、わずか 25 μL の血漿または血清、あるいは 50 μL の細胞培養上清のみを必要とし、分析結果を得るために要する時間もわずか 4 時間です。

次の特長があります。
• 再現性と信頼性の高い結果 — タンパク質標的の結合性および交差反応性試験など、業界最高水準のパネルとして検証済み
• サンプルあたりの結果の増加 — 25~50 μLのサンプル1つで複数のタンパク質標的を同時に測定
• 確立されたLuminex技術 - タンパク質の検出と定量化のための高度に参照されたマルチプレックスプラットフォーム

ProcartaPlexアッセイは、血漿、血清、細胞培養上清、およびその他の体液からの25~50 μLの単一サンプルで最大65のタンパク質標的を同時に検出および定量するためにLuminex xMAP(多項目同時測定プロファイリング)利用しています。

ProcartaPlex アッセイの Luminex ビーズは、赤および赤外フルオロフォアの正確な比率で内部染色されており、Luminex xMAP 検出システム(Luminex 200、FLEXMAP 3D、MAGPIX など)により識別できるスペクトル的に固有なシグネチャを生じます。サンドイッチ ELISA と同様に、ProcartaPlex アッセイはマッチした抗体ペアを使用して目的のタンパク質を同定します。マルチプレックスアッセイでは、スペクトル的に固有な各ビーズは単一の標的タンパク質に特異的な抗体で標識され、結合タンパク質がビオチン化抗体およびストレプトアビジン–R-フィコエリトリン(RPE)で同定されます。タンパク質特異的抗体の特異的なビーズへの結合により、1 つのウェルで複数のターゲットの分析が可能になります。

ProcartaPlexアッセイとELISAの最も大きな違いは、ProcartaPlexアッセイのキャプチャー抗体がビーズに結合され、マイクロプレートウェルに吸着されないことです。そのため、ProcartaPlexアッセイ試薬は溶液中で自由に浮遊します。

研究用途にのみご使用ください。診断目的には使用できません。
仕様
アッセイ範囲分析証明書を参照
アッセイ感度15%未満
検出法Fluorescence
使用対象 (装置)Luminex™ 装置
フォーマットMultiplex Kit
製品ラインProcartaPlex
サンプルタイプ血清、血漿、細胞培養上清, Plasma, Cell Culture Supernatants
サンプル量血清、血漿:25 μL、CCS:50 μL
出荷条件湿氷
CombinabilityCombinable
製品タイプマルチプレックスパネル
数量96テスト
Research AreaImmunology, Oncology
Human
Unit SizeEach
組成および保存条件
  • ヒト標準ミックスL(凍結乾燥)バイアル2本
  • キャプチャービーズミックス(1X)バイアル1本
  • ビオチン化検出抗体ミックス(50X)バイアル1本
  • 読み取りバッファー(1X)ボトル1本
  • 洗浄バッファー(10X)ボトル1本
  • ストレプトアビジン-PE(1X)ボトル1本
  • ユニバーサルアッセイバッファー(1X)ボトル1本
  • 検出抗体希釈液(1X)ボトル1本
  • 8チューブストリップ
  • 接着フィルム
  • 平底96ウェルプレート、黒
  • 2℃~8℃で保存してください

よくあるご質問(FAQ)

What is the size of the Luminex beads you currently use?

The beads used in our Luminex instrument-compatible ProcartaPlex and QuantiGene Plex assays are 6.5 micron superparamagnetic beads.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

I am interested in performing Luminex assays using BioSource kits, and I have a Luminex xMAP system. Besides the kits and system, what other reagents and equipment will I need?

The following is a list of general lab supplies that are required for running BioSource immunoassays on the Luminex xMAP system:
1) Sonicating water bath
2) Orbital shaker
3) Vortexer
4) Repeating and/or multi-channel pipetter (not required, but recommended)
5) Calibrated adjustable precision pipettes, with disposable plastic tips
6) Glass/plastic tubes and racks for preparing reagents
7) Graduated cylinder and container for preparing wash solution
8) Aluminum foil
9) Deionized or distilled water.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Do the Luminex beads require special care in handling?

The Luminex beads should be protected from light because they are susceptible to photobleaching. We recommend protecting the beads by keeping containers covered with aluminum foil during all incubation steps, and exercising care during handling. The beads should not be frozen, subjected to excessive heat, or exposed to organic solvents.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Why would the Luminex acquisition software display "Sample Empty" messages during analysis?

(1) The user did not properly aliquot the diluted beads, such that no beads were actually added to the wells (make sure that the bead concentrates are sonicated and vortexed well, then check the pipet tip to ensure that air bubbles were not drawn up)
(2) The user missed loading diluted beads to some wells, which is likely since the small volume is clear and difficult to visualize in the clear plastic plate (we have now addressed this customer difficulty by coloring each of the Buffer Reagent Kit components)
(3) The user applied too much vacuum pressure at some point during the wash steps, or allowed the pressure to spike even once, such that the filter membrane tore in a few wells releasing the beads (make sure that the vacuum manifold pressure is kept below 5mm/in Hg, depending on their system -- a good rule of thumb is that it should take a full 3-second count to GENTLY empty the wells of 200uL)
(4) The user did not properly sonicate and vortex the beads prior to dilution, such that the percent of bead aggregation was high and the instrument was unable to find enough single beads to meet the events/bead value designated by the customer (make sure that the Bead Concentrate tube is put into the waterbath all the way to the cap, since the tube is hollow until the top third)
(5) The user lost beads by shaking the plate too aggressively or handling it improperly (make sure that the orbital shaker is set to a speed that allows for maximum vortex in the wells without spillage)
(6) The user exposed the beads to an excess of light during storage or running of the assay, such that some but not all of the beads were photobleached and therefore falling outside the acceptable range for each bead region (make sure that the plate is covered on the top/sides with foil throughout the assay, away from Windows and spotlights, and that the bead component of the kits is stored in the dark)*
(7) There was a clog in the sample needle, such that the instrument was unable to take up enough sample to meet the number of events requested per bead region (suggest that the user follow the manual instructions for dislodging a clog, which include several Back Flush steps and may require removal of the needle for sonication with probe alignment).

* Some of the older Antibody Bead Kits still have clear plastic tops instead of black ones. In cases where customers store kits in lit refrigerators, or keep them open on the lab bench, even a few hours of light exposure is enough to photobleach beads. It is important to note, in general, that higher number bead regions are more susceptible to photobleaching. In order to draw conclusions about the source of the difficulty, we would ask to see the data, specifically the Masterplex QT file, which would enable us to examine the pattern of "Sample Empty" occurrences in addition to the bead counts per well.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

What are the Luminex beads made of?

The beads are made of polystyrene.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

引用および参考文献 (10)

引用および参考文献
Abstract
Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study.
Authors:Rodrigues-Santos P,Almeida JS,Sousa LM,Couceiro P,Martinho A,Rodrigues J,Fonseca R,Santos-Rosa M,Freitas-Tavares P,Casanova JM
Journal:Frontiers in immunology
PubMed ID:40007535
Soft tissue sarcomas (STS) encompass over 50 histologic subtypes, representing more than 1% of solid tumors. Standard treatments include surgical resection and therapies such as anthracyclines or trabectedin for advanced cases, though challenges persist due to the tumor microenvironment’s complexity and limited immune profiling data. This study evaluates Trabectedin therapy ... More
Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.
Authors:J. Gorgulho et al.
Journal:British Journal of Cancer
PubMed ID:38233492
The search for biomarkers to identify suitable candidates for immune checkpoint inhibitor (ICI) therapy remains ongoing. We evaluate how soluble levels of the next generation immune checkpoint Lymphocyte Activation Gene-3 (sLAG-3) and its association with circulating T lymphocyte subsets could pose as a novel biomarker to predict outcome to ICI ... More
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.
Authors:Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP, Mathur N, Zhou C, Coakley RV, Bartels A, Bowden M, Herbert Z, Hill S, Gilhooley S, Carter J, Cañadas I, Thai TC, Kitajima S, Chiono V, Paweletz CP, Barbie DA, Kamm RD, Jenkins RW
Journal:Lab Chip
PubMed ID:30183789
Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for clinical use to test novel cancer therapeutics. To be effective, these platforms need to replicate the continuous interactions that exist between tumor cells and non-tumor cell elements of the tumor microenvironment ... More
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Authors:Rolfes V, Idel C, Pries R, Plötze-Martin K, Habermann J, Gemoll T, Bohnet S, Latz E, Ribbat-Idel J, Franklin BS, Wollenberg B
Journal:Oncotarget
PubMed ID:29937998
Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies that target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown unprecedented rates of durable clinical responses in patients with various cancer types. However, there ... More
Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Authors:Wang Q, Zhang J, Tu H, Liang D, Chang DW, Ye Y, Wu X
Journal:J Immunother Cancer
PubMed ID:31783776
Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. With the exception of a few candidate biomarkers, the prognostic role of soluble immune checkpoint-related proteins in clear cell renal cell cancer (ccRCC) patients is largely uninvestigated. ... More